Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/1/2020
SIETES contiene 92881 citas

 
 
 1 a 20 de 275 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Bosch J, O'Donnell M, Swaminathan B, Lonn EM, Sharma M, Dagenais G, Diaz R, Khunti K, Lewis BS, Avezum A, Held C, Keltai M, Reid C, Toff WD, Dans A, Leiter LA, Sliwa K, Lee SF, Pogue JM, Hart R, Yusuf S, HOPE-3 Investigators. Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. Neurology 2019;92:26 de marzo. [Ref.ID 103120]
2. Cita con resumen
Akyea RK, Kai J, Qureshi N, Iyen B, Weng SF. Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. Heart 2019:15 de abril. [Ref.ID 103087]
3.Enlace a cita original Cita con resumen
Abdullah SM, Defina LF, Leonard D, Barlow CE, Radford NB, Willis BJ, Rohatgi A, McGuire DK, de Lemos JA, Grundy SM, Berry JD, Khera A. Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease results from the Cooper Center Longitudinal Study. Circulation 2018;138:16 de agosto. [Ref.ID 102796]
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
Navarese EP, Robinson JG, Kowatewski M, Kotodziejczak M, Andreotti F, Bliden K, Tantry U, Kubica J, Raggi P, Gurbel PA. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering. A systematic review and meta-analysis. JAMA 2018;319:17 de abril. [Ref.ID 102784]
5.Enlace a cita originalTiene citas relacionadas Cita con resumen
Navar AM, Peterson ED. Challenges in interpreting the lipid-lowering trials: biology vs ecology. JAMA 2018;319:17 de abril. [Ref.ID 102783]
6.Tiene citas relacionadas Cita con resumen
Diamond D, Kendrick M, Mascitelli L. Exaggerated report of benefits in a flawed long term statin treatment study. BMJ 2017;359:j4915. [Ref.ID 102120]
7.Tiene citas relacionadas Cita con resumen
Ravnskov U, Okuyama H, Sultan S. Serious bias in 20 year follow-up study of statin trial. BMJ 2017;359:j4906. [Ref.ID 102119]
8. Cita con resumen
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22. [Ref.ID 101586]
9. Cita con resumen
McGettigan P, Ferner RE. PCSK9 inhibitors for hypercholesterolaemia. BMJ 2017;356:j188. [Ref.ID 101397]
11.Enlace a cita originalTiene citas relacionadas
12.Tiene citas relacionadas
Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, Demets D, Evans S, Law M, McMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercok P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:2532-61. [Ref.ID 100988]
13.Enlace a cita originalTiene citas relacionadas
Redberg RF, Katz MH. Statins for primary prevention: the debate is intense, but the data are weak. JAMA 2016;316:1979-81. [Ref.ID 100987]
14.Enlace a cita originalTiene citas relacionadas
Greenland P, Bonow RO. Interpretation and use of another statin guideline. JAMA 2016;316:1977-9. [Ref.ID 100986]
15.Enlace a cita originalTiene citas relacionadas
Gurwitz JH, Go AS, Fortmann SP. Statins for primary prevention in older adults: uncertainty and the need for more evidence. JAMA 2016;316:1971-2. [Ref.ID 100985]
16.Enlace a cita originalTiene citas relacionadas
Thompson PD. What to believe and do about statin-associated adverse efects. JAMA 2016;316:1969-70. [Ref.ID 100984]
17.Enlace a cita originalTiene citas relacionadas
Rodríguez F, Harrington RA. Cholesterol, cardiovascular risk, statins, PCSK9 inhibitors, and the future of LDL-C lowering. JAMA 2016;316:1967-8. [Ref.ID 100983]
18. Cita con resumen
Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016;316:1289-97. [Ref.ID 100769]
19. Cita con resumen
Leibowitz M, Karpati T, Cohen-Stavi CJ, Feldman BS, Hoshen M, Bitterman H, Suissa S, Balicer RD. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic heart disease taking statin treatment. JAMA Intern Med 2016;176:1105-13. [Ref.ID 100700]
20. Cita con resumen
Ravnskov U, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Hynes N, Kendrick M, Langsjoen PH, Malhotra A, Mascitelli L, McCully KS, Ogushi Y, Okuyama H, Rosch PJ, Schersten T, Sultan S, Sundberg R. Lack of an association or an inverse association between low-density lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open 2016:28 de junio. [Ref.ID 100445]
Seleccionar todas
 
 1 a 20 de 275 siguiente >>